role of toclizumab in a patient with ARDS developed due to covid 19
Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related moality among patients requiring intensive care unit (ICU) suppo for COVID-19. ref : www.ncbi.gov
it acts by halting lysogenic phase of corona virus
it stops the lung parenchymal damge by the virus
it is a IL-6 receptor inhibitor
all the above
All India exam